PHRRF (PharmaTher Holdings) 3-Year ROIIC % : 1,163.41% (As of May. 2025) — 141% Above Median


What is PharmaTher Holdings 3-Year ROIIC %?

PharmaTher Holdings PHRRF +2.85% 3-Year ROIIC % is 1,163.41 as of May. 2025, which is 141% above its 10-year median of 482.63. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, PharmaTher Holdings ranks better than 94.7% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. PharmaTher Holdings's 3-Year ROIIC % for the quarter that ended in May. 2025 was 1,163.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for PharmaTher Holdings's 3-Year ROIIC % or its related term are showing as below:

PHRRF's 3-Year ROIIC % is ranked better than
94.7% of 1322 companies
in the Biotechnology industry
Industry Median: -4.82 vs PHRRF: 1163.41

PharmaTher Holdings  (OTCPK:PHRRF) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


PharmaTher Holdings 3-Year ROIIC % Related Terms


PharmaTher Holdings 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for PharmaTher Holdings's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaTher Holdings 3-Year ROIIC % Chart

PharmaTher Holdings Annual Data
Trend May21 May22 May23 May24 May25
3-Year ROIIC %
0.00 0.00 0.00 -198.16 1,163.41

PharmaTher Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,163.41 0.00 0.00 0.00

PHRRF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison

For the Biotechnology subindustry, PharmaTher Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaTher Holdings 3-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaTher Holdings's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where PharmaTher Holdings's 3-Year ROIIC % falls into.



PharmaTher Holdings 3-Year ROIIC % Calculation

PharmaTher Holdings's 3-Year ROIIC % for the quarter that ended in May. 2025 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -1.131 (May. 2025) - -3.020611 (May. 2022) )/( 0.145 (May. 2025) - 0.0020000000000007 (May. 2022) )
=1.889611/0.143
=1,321.41%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of 1,163.41 mean?
PharmaTher Holdings (PHRRF) has a 3-Year ROIIC % of 1,163.41 as of May. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PharmaTher Holdings and its competitors. This is 141% above median its historical median of 482.63. According to the industry distribution chart, PharmaTher Holdings ranks #70 out of 1322 companies in the Biotechnology industry, placing it in the top 5.3%.
Is PharmaTher Holdings' 3-Year ROIIC % too high?
PharmaTher Holdings' current 3-Year ROIIC % of 1,163.41 is 141% above median its 10-year median of 482.63. Based on the distribution chart, PharmaTher Holdings ranks #70 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does PharmaTher Holdings' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaTher Holdings ranks #70 out of 1322 companies for 3-Year ROIIC %. This places PharmaTher Holdings in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PharmaTher Holdings and its competitors. PharmaTher Holdings's current 3-Year ROIIC % is 1,163.41, which is 141% above median its own 10-year median of 482.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaTher Holdings stock overvalued right now?
PharmaTher Holdings (PHRRF) has a current 3-Year ROIIC % of 1,163.41. The current 3-Year ROIIC % is 1,163.41, which is 141% above median its 10-year median of 482.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For PharmaTher Holdings (PHRRF), the current 3-Year ROIIC % is 1,163.41 as of May. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaTher Holdings Business Description

Other Exchanges NCC0:GermanyPHRM:Canada
Address 82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch and others.